Methodology: 2/5
Usefulness: 1/5

Lim P, et al. Eur Heart J Acute Cardiovasc Care. 2022 Jan 12;11(1):2-9.

Question and Methods: Does diuresis with single-dose IV furosemide improve hemodynamic parameters and prevent oligo-anuria in normotensive patients with intermediate-risk PE? Multi-centre, placebo-controlled, double-blind trial of furosemide 80mg IV vs. placebo.
Findings: 135 of the 276 randomized patients received furosemide. 51.5% of the furosemide group achieve the composite primary outcome, compared to 37.1% in the placebo group (RR = 1.30, 95% CI 1.04-1.61; p = 0.021). No differences in major adverse outcomes were observed.
Limitations: The composite primary outcome is not patient-centered and included urine output, which is directly induced by the intervention. No explanation of how blinding was maintained. A single dose of furosemide has limited length of effect.

Interpretation: In normotensive patients with intermediate-risk PE, furosemide is unlikely to improve sPESI hemodynamic parameters, but may be beneficial in maintaining urine output.

Dr. Alexandre Coutin

JC Supervisor: Dr. Venkatesh Thiruganasambandamoorthy




  • Alex Coutin

    Dr. Coutin (he/they) is a senior Emergency Medicine resident at the University of Ottawa with special interests in social advocacy, 2SLGBTQ+ health, addictions, public health, POCUS, physician wellness, and medical education. He is a Senior Editor with the EMOttawa Digital Scholarship and Knowledge Dissemination team.

    View all posts
  • Hans Rosenberg

    Dr. Rosenberg is an emergency physician at the Ottawa Hospital, associate professor at the University of Ottawa, and Director of the Digital Scholarship and Knowledge Dissemination Program.

    View all posts
  • Venkatesh Thiruganasambandamoorthy

    Dr. Venkatesh Thiruganasambandamoorthy is an attending physician and associate scientist at the Ottawa Hospital and Ottawa Hospital Research Institute with an particular interest in syncope and presyncope care.

    View all posts